venBio Partners LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001776382 · Show all filings

Period: Q3 2023 (← Previous) (Next →)

Filing Date: Nov 14, 2023

Total Value: $353M (100.0% shares, 0.0% debt)

Holdings (8)

— RAYZEBIO INC 32.5%

Value $115M Shares 5,158,162 Est. Cost $22.20 Unrealized —

PHVS PHARVARIS N V 25.2%

Value $89M Shares 4,264,672 Est. Cost $21.29 Unrealized -13.4%

ALXO ALX ONCOLOGY HLDGS INC 13.2%

Value $46.56M Shares 9,699,925 Est. Cost $39.31 Unrealized -86.2%

— ACELYRIN INC 11.1%

Value $39.18M Shares 3,852,470 Est. Cost $20.90 Unrealized —

HRMY HARMONY BIOSCIENCES HLDGS IN 9.6%

Value $33.93M Shares 1,035,396 Est. Cost $36.46 Unrealized -4.8%

VTYX VENTYX BIOSCIENCES INC 7.5%

Value $26.35M Shares 758,800 Est. Cost $25.84 Unrealized +33.8%

— ELEVATION ONCOLOGY INC 0.5%

Value $1.931M Shares 2,914,255 Est. Cost $9.24 Unrealized —

— IMPEL PHARMACEUTICALS INC 0.3%

Value $1.187M Shares 2,759,791 Est. Cost $8.85 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	RAYZEBIO INC	5,158,162	$115M	32.5%	$22.20	—	COM	75525N107
PHVS	PHARVARIS N V	4,264,672	$89M	25.2%	$21.29	-13.4%	COM	N69605108
ALXO	ALX ONCOLOGY HLDGS INC	9,699,925	$46.56M	13.2%	$39.31	-86.2%	COM	00166B105
—	ACELYRIN INC	3,852,470	$39.18M	11.1%	$20.90	—	COM	00445A100
HRMY	HARMONY BIOSCIENCES HLDGS IN	1,035,396	$33.93M	9.6%	$36.46	-4.8%	COM	413197104
VTYX	VENTYX BIOSCIENCES INC	758,800	$26.35M	7.5%	$25.84	+33.8%	COM	92332V107
—	ELEVATION ONCOLOGY INC	2,914,255	$1.931M	0.5%	$9.24	—	COM	28623U101
—	IMPEL PHARMACEUTICALS INC	2,759,791	$1.187M	0.3%	$8.85	—	COM	45258K109